echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first in China! Idea Di AXL Inhibitor Application for Clinical

    The first in China! Idea Di AXL Inhibitor Application for Clinical

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 3, the application for the clinical trial of the 3D-229 injection of Silide Di's AXL inhibitor was officially accepted by CDE, and it was the first AXL inhibitor to be declared for clinical use in China.


    3D-229 (AVB-500), developed by Aravive of the United States, on November 11, 2020, Sidi Di obtained the exclusive development and commercialization rights of 3D-229 in the oncology field of Greater China from Aravive for a total of 219 million US dollars.


    The GAS6-AXL signaling pathway is a key pathway that promotes tumor growth and metastasis, tumor immune escape and drug tolerance.


    The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.


    Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).


    At present, clinical trials of AVB-500 for renal cell carcinoma and urothelial cancer are also underway, and it has obtained fast-track qualification granted by the FDA for platinum-resistant recurrent ovarian cancer indications.


    Source: Aravive official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.